Qiagen (NYSE:QGEN) Announces Quarterly Earnings Results

Qiagen (NYSE:QGEN) issued its earnings results on Tuesday. The company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.58 by $0.03, Zacks reports. Qiagen had a net margin of 18.30% and a return on equity of 14.77%. The firm had revenue of $533.00 million during the quarter, compared to the consensus estimate of $525.68 million. During the same quarter in the prior year, the firm earned $0.57 earnings per share. The business’s quarterly revenue was up 6.2% on a year-over-year basis. Qiagen updated its FY 2025 guidance to 2.380-2.380 EPS and its Q4 2025 guidance to 0.600-0.600 EPS.

Qiagen Stock Down 3.4%

Qiagen stock opened at $44.13 on Wednesday. The stock has a market capitalization of $9.81 billion, a PE ratio of 26.07, a price-to-earnings-growth ratio of 2.48 and a beta of 0.66. Qiagen has a twelve month low of $37.63 and a twelve month high of $51.88. The company has a quick ratio of 1.35, a current ratio of 1.61 and a debt-to-equity ratio of 0.25. The company has a 50 day moving average of $46.66 and a 200-day moving average of $46.48.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Cowen reaffirmed a “hold” rating on shares of Qiagen in a research note on Thursday, August 7th. UBS Group upped their target price on shares of Qiagen from $48.00 to $50.00 and gave the company a “neutral” rating in a research note on Thursday, August 7th. Barclays set a $53.00 target price on shares of Qiagen and gave the company an “overweight” rating in a research note on Thursday, October 2nd. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Qiagen in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised shares of Qiagen from a “hold” rating to a “buy” rating in a research note on Saturday. Three research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $49.69.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in QGEN. Invesco Ltd. grew its position in Qiagen by 123.7% in the second quarter. Invesco Ltd. now owns 1,006,025 shares of the company’s stock valued at $48,350,000 after purchasing an additional 556,387 shares in the last quarter. Quantinno Capital Management LP grew its position in Qiagen by 150.5% in the second quarter. Quantinno Capital Management LP now owns 141,403 shares of the company’s stock valued at $6,792,000 after purchasing an additional 84,964 shares in the last quarter. Ameriprise Financial Inc. grew its position in Qiagen by 26.4% in the second quarter. Ameriprise Financial Inc. now owns 112,617 shares of the company’s stock valued at $5,412,000 after purchasing an additional 23,524 shares in the last quarter. PDT Partners LLC grew its position in Qiagen by 142.4% in the second quarter. PDT Partners LLC now owns 110,563 shares of the company’s stock valued at $5,314,000 after purchasing an additional 64,956 shares in the last quarter. Finally, First Trust Advisors LP bought a new position in Qiagen in the second quarter valued at $3,639,000. Institutional investors and hedge funds own 70.00% of the company’s stock.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.